Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Views & Analysis Budget impact and cost effectiveness: Can the UK learn from ... Leela Barham examines the approach of the Institute for Clinical and Economic Review.
Views & Analysis The budget impact of new medicines What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
